What are the reference strains of *Acinetobacter baumannii* referring to?

Chantal Philippe¹ *, Adam Valcek^{2, 3} *, Clémence Whiteway^{2, 3}, Etienne Robino^{2, 3}, Kristina Nesporova³, Mona Bové⁴, Tom Coenye⁴, Tim De Pooter^{5, 6}, Wouter De Coster^{7, 8}, Mojca Strazisar^{5, 6}, Johanna Kenyon⁹ and Charles Van der Henst^{1, 2, 3} #

* These authors contributed equally to the study.

Corresponding author: charles.vanderhenst@vub.vib.be

Affiliations

¹ Research Unit in the Biology of Microorganisms (URBM), NARILIS, University of Namur (UNamur), Belgium.

² Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.

³ Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

⁴ Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

⁵ Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.

⁶ Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

⁷ Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium

⁸ Applied and Translational Neurogenomics Group, Department of Biomedical Sciences,
University of Antwerp, Antwerp, Belgium

⁹ School of Biomedical Sciences, and Infection and Immunity Program, Institute of Health and
Biomedical Innovation (IHBI), Faculty of Health, Queensland University of Technology,
Brisbane, Australia.

Abstract

We assembled the whole genome sequence (WGS) of a collection of 43 non-redundant modern
clinical isolates and four broadly used reference strains of *Acinetobacter baumannii*.
Comparison of these isolates and their WGS confirmed the high heterogeneity in capsule loci,
sequence types, the presence of virulence and antibiotic resistance genes. However, a
significant portion of clinical isolates strongly differ when compared to several reference strains
in the light of colony morphology, cellular density, capsule production, natural transformability
and *in vivo* virulence. These genetic and phenotypic differences between current circulating
strains of *A. baumannii* and established reference strains could hamper the study of *A.*
baumannii as an entity. The broadly used reference strains led to the current state of the art of
the *A. baumannii* field, however, we propose that established reference strains in the *A.*
baumannii field should be carefully used, because of the high genetic and phenotypic
heterogeneities. In this study, we generated a collection of high-quality nucleotide sequences
of 43 modern and non-redundant clinical isolates with the corresponding multi-level phenotypic
characterizations. Beside the contribution of novel fundamental observations generated in this
study, the phenotypic and genetic data, along with the bacterial strains themselves, will be
further accessible using the first open access online platform called “Acinetobase”. Therefore,

a rational choice of modern strains will be possible to select the ones that suit the needs of specific biological questions.

Introduction

Antibiotics overuse, along with fewer new therapeutics, represents a major challenge for human health (Hernando-Amado et al., 2019; Poirel and Nordmann, 2006). Multidrug-resistant (MDR) bacteria are increasingly isolated around the world, leaving physicians increasingly facing no therapeutic option (Murray et al., 2022). As a direct consequence, patients are currently dying from previously treatable diseases. In this context, WHO and CDC prioritize problematic bacterial pathogens for which antibiotic resistance significantly impacts human health (Centers for Disease Control, 2019; Tacconelli et al., 2018). *Acinetobacter baumannii* (Whiteway et al., 2022), a member of the ESKAPE multidrug-resistant and most problematic nosocomial pathogens (de Oliveira et al., 2020), was designated as a top-priority and critical agent for which therapeutic alternatives are urgently required (Tacconelli et al., 2018).

A. baumannii is a Gram-negative opportunistic bacterial pathogen that thrives in hospital settings, especially in intensive care units where weakened patients are treated (Whiteway et al., 2022). Beside their intrinsic and acquired antibiotic resistance, *A. baumannii* resistance to desiccation and disinfectants render any decontamination strategy a real challenge (Chiang et al., 2018). One key aspect sustaining the rapid spread of antibiotic resistance amongst *A. baumannii* isolates is their natural competence (Vesel and Blokesch, 2021). *A. baumannii* bacteria undergo horizontal gene transfer during which exogenous DNA is taken up and integrated within the bacterial genome (da Silva and Domingues, 2016). As a direct consequence, rapidly evolving *A. baumannii* bacteria show a dynamic genome, with an

estimated core (conserved) genome of only 16.5%, while 25% of the genome is unique to each strain, having no counterpart in any other *A. baumannii* genome (Imperi et al., 2011). However, despite their clinical relevance, *A. baumannii* bacteria remain poorly understood. Especially, their virulence and non-antibiotic associated resistance (disinfectants, desiccation etc.) still needs to be better characterized (Harding et al., 2017). One possible explanation for this gap of knowledge is the heterogeneity amongst *A. baumannii* isolates, rendering the multiple approaches of typing of this bacterial species, with as a proof-of-concept the huge diversity of the polysaccharide capsules and the outer core of the lipooligosaccharide (LOS) in *A. baumannii*, as well as two multilocus sequence typing (MLST) schemes (Gaiarsa et al., 2019). The LOS is present in *A. baumannii* instead of the common lipopolysaccharide (LPS). Unlike LPS, the LOS is lacking the O-antigen and is composed of lipid A with variable amounts of inner and outer core sugars (Kenyon et al., 2014). The outer sugars of LOS show diversity across strains, dependent on glycosyltransferases and nucleotide-sugar biosynthesis enzymes encoded in a highly variable outer core locus (OCL) (Geisinger et al., 2019).

The lipid composition of the outer membrane is involved in resistance to desiccation by retaining water and nutrients within the bacterial cell (Boll et al., 2015; Sarshar et al., 2021). Bacterial capsules consist of a polysaccharide layer deposited as the outermost surface exposed leaflet on prokaryotic cells, impacting the virulence and antibiotics, as well as non-antibiotics-based resistance (Dong et al., 2006; Niu et al., 2019). The locus encoding the genes involved in the production and the assembly of the polysaccharide capsule (KL) is chromosomally encoded and typically ranges from 20 to 35 kb in size. Its genetic organization comprises three modules (Kenyon and Hall, 2013) encoding (i) the export machinery consisting of three proteins; Wza, Wzb, and Wzc, (ii) glycosyltransferases and the capsule processing genes (and optionally genes for the synthesis and modification of complex sugars) and (iii), genes involved in the synthesis of simple sugar substrates. Another part of the capsular polysaccharide (CPS) used in typing

schemes is the OCL of LOS. The LOS of the outer membrane is a major virulence component in Gram-negative bacteria. The OCL, similarly as KL, is encoded chromosomally and to date 14 variants (differing in the presence or absence of genes encoding multiple glycosyltransferases and other enzymes) were described. OCL types can be divided in two groups (A or B) based on the presence of *pda1* and *pda2* genes (Kenyon et al., 2014). The OCL consists of genes involved in the synthesis, assembly and export of complex oligosaccharides that are then linked to lipid A to form the LOS (Kenyon and Hall, 2013).

Witnessing the high diversity amongst *A. baumannii* isolates, our approach aims at investigating to which extent the use of reference strains actually reflects the dynamic nature and intrinsic heterogeneity of these bacteria in general, at the phenotypic and genotypic level. In this study, we assessed the phenotypic and genetic diversity levels of 43 *A. baumannii* modern clinical isolates, and we compared them to established type strains of *A. baumannii* in the field: AB5075, ATCC17978, ATCC19606 and DSM30011 which are widely used in various studies (Bravo et al., 2016; de Silva et al., 2017; Jacobs et al., 2014; Roussin et al., 2019).

Materials and Methods

Modern clinical isolates, reference strains and phylogeny inference

A non-redundant collection of 43 modern (not older than 8 years) clinical isolates from the National Reference Center for Antibiotic-Resistant Gram-Negative Bacilli (CHU UCL-Namur) and four established reference strains: ATCC17978-VUB, ATCC19606-VUB, DSM30011-VUB and AB5075-VUB were studied. The reference strains AB5075, ATCC17978 and ATCC19606 are non-MDR (except AB5075) strains of clinical (osteomyelitis, meningitis and urine, respectively) origin (Gallagher et al., 2015; Harding et al., 2017) while DSM30011 is a non-MDR environmental strain obtained from plant microbiota (Repizo et al., 2017). The

reference strains were designated with the extension “-VUB” in order to distinguish the strains and their sequences examined within our study. The selected isolates were described in our previous study (Valcek et al., 2021). In order to increase the heterogeneity of the collection, three carbapenem-susceptible isolates (AB21-VUB, AB169-VUB and AB179-VUB) were added and analyzed as well. We sequenced the whole genome of these isolates using short reads (Illumina) combined with long reads [Oxford Nanopore Technologies (ONT)] sequencing techniques to generate *de novo* assembled genomes for each of them.

Short- and long-read sequencing

Genomic DNA extraction and the sequencing library preparation for short-read 2x250 bp paired-end MiSeq (Illumina) sequencing was performed as described before (Valcek et al., 2021). The DNA for long-read MinION (ONT) sequencing was extracted using Genomic-tip 100/G (Qiagen, Hilden, Germany). The long-read sequencing libraries were prepared using 1D Ligation Barcoding Kit (SQK-LSK109 and EXP-NBD104 ONT, Oxford, UK). Samples were QCed using Qubit (dsDNA BR chemistry, Thermo Fisher Scientific), and Fragment Analyzer, Agilent Technologies (using DNF-464 kit). Average size of the fragments was 45-70 kb. Samples were equimolarly pooled and run per 12 in one run which was always 2x reloaded. MinION flowcells had min. 1200 sequencable pores at the start and initial loading was approximately 35 fmol followed by 2 reloads each after 24h into sequencing. The sequencing was performed on MinION Mk1b (ONT) using R9.4.1 (FLO-MIN106) flowcells.

Sequence data analysis

The long-reads sequences were demultiplexed and basecalled using Guppy v3.2.2 and subsequently were adaptor, quality ($Q \leq 13$) and length (5000 bp) trimmed using Porechop v0.2.2 (<https://github.com/rrwick/Porechop>) and NanoFilt v2.8.0 (de Coster et al., 2018.),

respectively. The short reads (BioProject PRJNA734485) were used to polish the long reads employing Ratatosk v0.7.0 (Holley et al., 2021). The corrected reads were then assembled using Flye v2.9 (Kolmogorov et al., 2019) resulting in circular chromosomal contigs of all isolates. The circularity was verified by mapping short reads to corresponding assemblies in order to observe overlapping sequences. The circular chromosomal contigs were polished using long reads via racon v1.4.20 (<https://github.com/isovic/racon>) and Medaka v1.2.2 (<https://github.com/nanoporetech/medaka>) and subsequently by quality ($Q \leq 20$) and adaptor trimmed (using Trimmomatic (Bolger et al., 2014)) short reads in three rounds of Pilon (Walker et al., 2014) polishing.

Antimicrobial resistance genotype and phenotype

The antimicrobial susceptibility testing and characterization of its genetic background was performed and described in our previous study (Valcek et al., 2021).

Natural competence of the isolates

The natural competence of the clinical isolates and reference strains of *A. baumannii* was assessed by starting an overnight bacterial culture from -80°C stock in 5mL of LB (37°C at 160 rpm). The culture was diluted 1:100 in 2mL microtube (10µL of the bacterial culture + 990µL tryptone solution of 5g/L). Then 3µL of the diluted culture was mixed with 3µL of plasmid DNA (100ng/µL) in 1mL microtube. Subsequently, 3µL of the mix of culture and plasmid DNA was transferred to a 2mL microtube containing 1mL tryptone 5g/L agar 2%. A 3µL of diluted bacterial culture without plasmid DNA was used as a negative control.

After 6h incubation at 37°C, 100µL of tryptone solution at 5g/L was added to the microtube with the culture and plasmid DNA and vortexed gently. A 50µL of the suspension was plated on LB agar plates containing apramycin (50µg/mL) to select transformants. The negative

control was plated apramycin LB agar plates too. Colonies were counted after overnight incubation at 37°C.

Hemolytic and protease activities

To assess the potential hemolytic activities of the different *A. baumannii* isolates, we spotted 5 µl of an O/N (overnight) culture of bacteria previously grown in LB medium for 16 hours at 37°C under constant agitation (175 rpm) on 4 different Blood Agar Plates: (i) Columbia Agar with 5% Horse Blood, (ii) Columbia Agar with 5% Sheep Blood, (iii) Trypticase™ Soy Agar II with 5% Horse Blood and (iv) Trypticase™ Soy Agar II with 5% Sheep blood, all purchased from BD (Becton, Dickinson and Company, Franklin Lakes, NJ). To test for secreted protease activity, we used the same approaches as described above and spotted the 5 µl of bacteria on LB agar plates containing 2% of Skim Milk Powder for microbiology (Sigma-Aldrich/Merck KGaA, Darmstadt, Germany). Plates were incubated at 25°C and monitored for hemolytic and protease activities after 1, 2 and 6 days of incubation.

Phylogenetic analysis

The maximum-likelihood tree depicting the relatedness of the isolates was constructed from assembled complete genomes using predicted open reading frames obtained by Prokka (Seemann, 2014) as an input for the core-genome alignment created using Roary (Page et al., 2015). RAxML (Stamatakis, 2006) was used for calculation of the phylogenetic tree using general time reversible with optimization of substitution rates under GAMMA model of rate heterogeneity method supported by 500 bootstraps. The phylogenetic tree was visualized in iTOL (Letunic and Bork, 2019).

Genotypic characterization

The resistance and virulence genes were detected using ABRicate (https://github.com/tseemann/abricate) employing ResFinder 4.1 (Bortolaia et al., 2020), VFDB 2022 (Liu et al., 2022) and MEGARes 2.0 (Doster et al., 2020) databases, respectively with 90% threshold for both gene identity and coverage. The typing of capsule-encoding loci (KL) and lipooligosaccharide outer core (OCL) were determined using Kaptive (Wick et al., 2018; Wyres et al., 2020) after manual curation of the corresponding loci by mapping the short reads on anticipated reference sequence of the KL using Geneious R9 (Biomatters, NZ).

Macrocolony morphology

5 µl of overnight bacterial suspension (~ 1x10⁸ cells) was plated on Columbia Agar with 5% Sheep Blood purchased from BD (Becton, Dickinson and Company, Franklin Lakes, NJ). The plates were incubated non-inverted for 24h at 25°C and subsequently photographed by a Canon® camera.

Capsule production

1 ml of overnight culture in a 1.5 ml microtube was centrifuged for 2 min at 7000 rcf. The supernatant was removed, and the pellet was resuspended in 1 ml of PBS. Subsequently, 875 µl of PBS resuspended bacteria were mixed with 125 µl of LUDOX® LS colloidal silica (30 wt. % suspension in H₂O, Merck) (Ardissone et al., 2014; Kon et al., 2020). This mix was then centrifuged for 30 min at 12.000 rcf and immediately photographically recorded.

Transmission electron microscopy (TEM)

Transmission electron microscopy (TEM) was used for direct capsule visualization by labeling the capsule of 11 *A. baumannii* isolates, 9 modern clinical isolates and 3 reference strains, which ranges from high to low densities. The fixation and staining of the bacteria were performed as

described before (Chin et al., 2018). The cupule with the fixed pellet of bacteria (polymerized for 5 hours) was embedded in resin and polymerized (12h at 37°C, 48h at 45°C and 3 days at 60°C). The ~60 nm slides of the resin were marked with acetate uranyl and placed on the electron microscopy grid.

Virulence in *Galleria mellonella* model of infection

TruLarv research grade larvae of *G. mellonella* (BioSystems Technology) were stored at 15°C no longer than 5 days after arrival and were incubated for 30 min at 4°C prior to injection. Bacteria from an overnight culture were washed with physiological saline (PS) (0.9% NaCl) and diluted to approx. 1×10^7 CFU/ml. The larvae were injected with 10 µl of PS containing 1×10^5 CFU/ml of *A. baumannii* in the last left proleg using a 0.3 ml insulin syringe (BD MicroFine). Each of the nine selected strains of *A. baumannii* were injected into 10 larvae and 10 larvae were injected with PS as a negative control. The experiments were carried in duplicates and the survival (assessed by keratinization and mobility) rate was evaluated each day in a period of 5 days.

Results

Genotypical characterization of the isolates

We have previously described the sequence types (ST) and the antibiotic resistance profiles of 40 modern carbapenem-resistant clinical isolates of *A. baumannii* bacteria (Valcek et al., 2021). We completed our strain collection by generating the whole genome sequence (WGS) of three carbapenem-sensitive modern isolates (AB21-VUB, AB169-VUB and AB179-VUB) and four broadly used reference strains in the *A. baumannii* field (AB5075-VUB, ATCC19606-VUB, ATCC17978-VUB and DSM30011-VUB), their phylogenetic tree and antimicrobial resistance genes (Supplementary Figure 1).

We further investigate the genetic background of our extended strain collection and generate polished *de novo* assembled genomes by combining Illumina and Oxford Nanopore Technologies sequencing data. Comparison of the whole genome sequences (WGS) of the 43 modern clinical isolates and four reference strains of *A. baumannii*, identified a core genome containing 2009 genes (Figure 1), representing 14.76% of coding sequences (CDS) from the pan-genome of 13611 CDS. The more *A. baumannii* genomes are analyzed, the more unique genes are identified (Figure 2B) while the number of conserved genes decreased. These findings confirm the great variability of *A. baumannii* bacteria, pointing towards a still open pan-genome of *A. baumannii* bacteria that are often changing. Therefore, we still make the current prediction that, every time a new isolate of *A. baumannii* is sequenced, most likely (a) novel gene(s) would be identified.

We further analyzed the 47 genomes of our strain collection in regard to their respective sequence type (ST), capsule locus type (KL) and lipooligosaccharide locus (OCL) types. Twelve ST groups were identified, with ST2 as the most prevalent (25/43) followed by ST636 (6/43), ST1 (4/43), ST85 (2/43), ST78 (2/43) and ST604, ST215, ST158 and ST10 (one isolate each) (Figure 2). The four reference strains belong to ST1 (AB5075-VUB), ST52 (ATCC19606-VUB), ST437 (ATCC17978-VUB) and ST738 (DSM30011-VUB). We found that the most frequent capsule type was KL40 (10/43) followed by KL9 (6/43), KL3 (5/43), KL2 (4/43), KL13 and KL4 (3/43), KL22 and KL6 (2/42) and KL125, KL124, KL81 KL58, KL18, KL12, KL10 and KL7 (one isolate each) (Figure 2). We confirmed that the reference strains ATCC19606-VUB and ATCC17978-VUB, both belonged to KL3, while DSM30011-VUB to KL47 and AB5075-VUB to KL25 (Arbatsky et al., 2015; Senchenkova et al., 2015; Wang-Lin et al., 2017). In this regard, the reference strains ATCC19606-VUB and ATCC17978-VUB, both KL3, were more representative than DSM30011-VUB (KL47) and AB5075-VUB (KL25) which were sole to be of said KL. The typing of the locus encoding the

OCL of the LOS revealed high occurrence of OCL1 (31/43) followed by OCL2 (7/43), OCL6 and OCL3 (2/43) and OCL5 (1/43). We confirmed that the reference strains belonged to OCL2 (AB5075-VUB and ATCC17978-VUB), OCL3 (ATCC19606-VUB) and OCL6 (DSM30011-VUB).

The phylogenetic along with the genetic analyses of KL and OCL showed that, except for AB5075-VUB, the reference strains ATCC17978-VUB, ATCC19606-VUB and DSM30011-VUB only clustered with the clinical isolates of rare ST and KL. Despite AB5075-VUB was sole of the KL25 it clustered closer to the modern clinical isolates of *A. baumannii*. In addition, a variety of genes from operons encoding RND efflux pumps involved in virulence were not present in said three oldest reference strains (ATCC19606-VUB, ATCC17978-VUB and DSM30011-VUB), and a key gene involved in biofilm formation (*bap*) was undetected in all reference strains (Figure 2). Employing MEGARes 2.0 database, only reference strain AB5075-VUB encoded all three RND efflux pumps *adeIJK*, *adeABC*, and *adeFGH*, while DSM30011-VUB, ATCC17978 and ATCC19606-VUB had an incomplete *adeABC* (lacking *adeC*, all three strains) and/or *adeFGH* (lacking *adeF*, DSM30011-VUB, ATCC19606-VUB) operon. Besides these three reference strains, only six modern clinical MDR strains of *A. baumannii* contained one or more incomplete operons encoding RND efflux pumps.

Figure 1 and 2. Bottom of the file (horizontally oriented)

Natural competence of *A. baumannii* clinical isolates and strains

We next assessed the natural competence ability of all the *A. baumannii* strains. The reference strain AB5075-VUB was used as a positive control due to its high competence in the tested conditions (Le et al., 2021). We have categorized the strains in regard to its level of competence (Table 1). These results are showing not only variability in the natural competence of the

clinical isolates and reference strains of *A. baumannii*, but also a different level of the natural competence.

Table 1: A table summarizing number of colonies of *A. baumannii* clinical isolates and reference strains detected after the transformation with plasmid containing apramycin cassette. High: >50 colonies; Medium: 30 – 50 colonies; Low: <5 colonies; Not detected – 0 colonies; in the tested conditions. ND – Not Detected.

Strain	Level of competence	Strain	Level of competence
DSM30011-VUB	Medium	AB181-VUB	ND
ATCC17978-VUB	ND	AB183-VUB	ND
ATCC19606-VUB	ND	AB186-VUB	High
AB3-VUB	ND	AB187-VUB	ND
AB9-VUB	ND	AB188-VUB	Low
AB14-VUB	ND	AB189-VUB	High
AB16-VUB	ND	AB193-VUB	ND
AB20-VUB	High	AB194-VUB	ND
AB21-VUB	ND	AB212-VUB	ND
AB32-VUB	Low	AB213-VUB	ND
AB36-VUB	ND	AB214-VUB	ND
AB39-VUB	ND	AB216-VUB	ND
AB40-VUB	ND	AB217-VUB	ND
AB167-VUB	ND	AB219-VUB	ND
AB169-VUB	High	AB220-VUB	ND
AB171-VUB	ND	AB222-VUB	High
AB172-VUB	ND	AB224-VUB	ND
AB173-VUB	ND	AB226-VUB	ND
AB175-VUB	ND	AB227-VUB	High
AB176-VUB	High	AB229-VUB	High
AB177-VUB	ND	AB231-VUB	ND
AB179-VUB	ND	AB232-VUB	High
AB180-VUB	ND	AB233-VUB	ND

Colony morphology of *A. baumannii* and the need for classification to define new phenotypic categories

304 We have now confirmed the high heterogeneity at the genetic level amongst our strain
305 collection of MDR modern clinical isolates (Figure 1). To test whether this observation
306 correlates with different levels of phenotypic heterogeneity, we spotted each strain on different
307 blood and milk derived media and observed the potential hemolytic or secreted protease
308 activities (Van der Henst et al., 2018) as well as the ultrastructure of macrocolonies (Figure 3).
309 The clinical isolates and the reference strains did not show detectable hemolytic or protease
310 activities in the tested conditions, which is a common trait amongst *A. baumannii* bacteria
311 (Bouvet and Grimont, 1986) (Figure 1). The reference strains AB5075-VUB, DSM30011-
312 VUB, ATCC17978-VUB and ATCC19606-VUB do represent this common phenotypic trait,
313 despite the high genetic diversity observed, confirming that the tested modern clinical isolates
314 did not acquire increased hemolytic nor secreted protease activities. However, the analysis of
315 the macrocolonies morphology highlights an important diversity level of the modern clinical
316 isolates compared to the reference strains. As shown in Figure 3 and Table 2, we observed at
317 least five different categories of ultrastructure of macrocolony for the modern clinical isolates
318 and only two categories for the tested reference strains, with the more modern isolate AB5075-
319 VUB being different compared to the three other reference strains DSM30011-VUB,
320 ATCC17978-VUB and ATCC19606-VUB. We could identify six constitutive mucoid strains
321 in the macrocolony type (MT) “A” group of *A. baumannii* isolates (Figure 3B). The colonies
322 of the isolates with constitutive mucoid phenotype had circular shape and smooth margin. The
323 least frequent morphology of a colony and second most mucoid was circular with raised top of
324 darker white color with only three isolates, representing the MTB group (Figure 3B). The most
325 abundant (n=17) type of colony (MTC) was irregular with translucent bottom and opaque top
326 with irregular margin. This group also includes the most modern reference strain AB5075-VUB
327 (Figure 3A). The isolates of the MTD group (n=14) produced circular colonies with undulate
328 margin and volcano shaped center. Most of the reference strains belongs to the MTE group of

seven least mucoid isolates (Figure 3B) with circular shape, translucent center and opaque outer ring. Hence, the shapes of the colonies allowed to divide the isolates into five macrocolony type groups with one representative isolate depicted in Figure 3 (Table 2).

Figure 3: Diversity of the macrocolony types of the reference strains (A) compared to modern clinical isolates (B) grown on columbia agar plates with 5% sheep blood. Scale bar: 1 cm.

Table 2: A table dividing the reference strains and the clinical isolates to five categories (MTA-MTE) based on the colony morphology from the most mucoid phenotype (A) to the least mucoid phenotype (E). Each category is represented by one isolate, which is depicted in Figure 3B.

Macrocolony Type (MT)	AB233-VUB (MTA)	AB227-VUB (MTB)	AB181-VUB (MTC)	AB40-VUB (MTD)	AB180-VUB (MTE)
	AB3-VUB	AB16-VUB	AB14-VUB	AB9-VUB	AB32-VUB
	AB39-VUB	AB20-VUB	AB21-VUB	AB36-VUB	AB212-VUB
	AB173-VUB		AB169-VUB	AB167-VUB	AB213-VUB
	AB177-VUB		AB171-VUB	AB175-VUB	ATCC17978-VUB
			AB172-VUB	AB176-VUB	ATCC19606-VUB
			AB186-VUB	AB179-VUB	DMS30011-VUB
			AB188-VUB	AB183-VUB	
			AB193-VUB	AB187-VUB	
			AB194-VUB	AB189-VUB	
			AB217-VUB	AB214-VUB	
			AB219-VUB	AB216-VUB	
			AB220-VUB	AB222-VUB	
			AB224-VUB	AB226-VUB	
			AB229-VUB		
			AB231-VUB		
			AB232-VUB		
			AB5075-VUB		

Capsule production of *A. baumannii*

As the mucoid phenotype can reflect the presence of an abundant polysaccharide capsule surrounding bacteria, we established a density gradient assay to assess encapsulation level of all *A. baumannii* isolates in a medium to high throughput level (Figure 4) (Whiteway et al., 2021). In this phenotypic assay, low density bacteria have a high capsulation level, while denser bacteria have lower capsulation levels (Figure 4A). A high heterogeneity degree concerning the density of *A. baumannii* bacteria, crossing the full range from low to high density levels is observed (Figure 4D). Interestingly, four clinical isolates were divided into two fractions, suggesting diversity in production of CPS even within the same isolate, possibly pointing towards a high frequency of phase variation leading to phenotypic heterogeneity previously described (Tipton et al., 2015). In majority, the reference strains show high densities except for AB5075-VUB characterized by a medium density level. Despite having low capsulation levels, the ATCC19606-VUB isolate constantly shows a lower density compared to the strain ATCC17978-VUB. On the other hand, none of the high-density isolates belonged to KL40, unlike majority of low-density producers, pointing towards causality. While in high density isolates no other pattern than frequent occurrence of ST2 (10/15) was observed, the isolates of low density were often of KL40 (7/9) of ST2 (5/9) or ST636 (4/9). In conclusion, we could not attribute a specific cell density with the capsule type. The colony morphology (MTE) and the density gradient of four modern clinical isolates of our collection (AB32-VUB, AB180-VUB, AB212-VUB and AB213-VUB) resembles those of the low capsulated reference strains ATCC17978-VUB, ATCC19606-VUB and DSM30011-VUB, hence was to a certain extent represented by two reference strains. In this regard, the reference strain AB5075-VUB represented 17 clinical isolates of MTC, yet the density gradients of this group were too heterogenous to be represented by a sole reference strain AB5075-VUB. However, the majority

(n=22/43) of the modern clinical isolates was not represented by the reference strains of *A. baumannii* considering the capsule production (density gradient) and macrocolony types.

Figure 4: (A) Depiction of the density gradient measuring principle. (B) Capsulation level of the reference strains and (C) comparison of various levels of capsulation of the modern clinical strains of *A. baumannii*. (D) Quantification of the density of bacterial cells measured in a gradient colloidal silica; standard deviation was calculated from biological triplicates.

372

373 To directly observe capsule deposition and thickness at high resolution and at the single cell
 374 level, we combined capsule labeling with transmission electron microscopy (TEM) approach
 375 (Figure 5). As expected, high density bacteria are surrounded by a denser and thicker capsule
 376 compared to low density bacteria (Figure 5B). Concerning the reference strains, we confirm
 377 AB5075-VUB to be the more capsulated reference strain tested in this study. We could not
 378 detect any capsule deposition on the ATCC17978-VUB strain and the ATCC19606-VUB
 379 shows weak and heterogeneously deposited layer in the tested conditions. This is in line with
 380 the reference strain ATCC19606-VUB being less dense compared to the reference strain
 381 ATCC17978-VUB in our density gradient assay (Figure 4D). Two less capsulated modern
 382 strains, the AB180-VUB and AB183-VUB also show high densities (in density gradient assay)
 383 with less abundant capsule deposition. The least dense isolates AB3-VUB, AB193-VUB and
 384 AB213-VUB show a high abundance of capsule formation. Accordingly, the strains AB36-
 385 VUB that shows an intermediate density level have an intermediate capsule deposition level
 386 while the AB39-VUB strain reaches a higher density with less capsule deposition. Taken
 387 together, these data show that bacterial density correlates with capsule abundance of *A.*
 388 *baumannii* bacteria and that the reference strains does not show all the heterogeneity observed
 389 in the modern clinical isolates tested regarding capsule production level.

390

Figure 5: A TEM direct capsule visualization of three reference strains (A) and 8 modern clinical strains (B) of various cell densities. Scale bar: 500 nm.

Constitutive mucoid strains are not hyper-virulent

As constitutive mucoid strains were observed only amongst the group of the modern MDR clinical isolates, we wondered if this phenotype could be associated with a higher *in vivo* virulence potential. *Galleria mellonella* larvae were infected with highly, medium, and weakly capsulated isolates, while the AB5075-VUB reference strain was used as a positive control of virulence (Jacobs et al., 2014). Concerning the constitutive mucoid isolates, while the AB213-VUB is highly virulent, the constitutive mucoid isolates AB3-VUB and AB233-VUB are weakly virulent (Figure 6). The medium capsulated isolate AB39-VUB was highly virulent and killed 100% of the larvae within one day, being even more virulent than the AB5075-VUB,

while the medium capsulated AB36-VUB showed an intermediary virulence level. Interestingly, the low capsulated isolates (AB183-VUB and AB180-VUB) were the less virulent, AB180-VUB being avirulent in the tested conditions (Figure 6). These data show that a constitutive high capsulation and mucoid phenotype does not correlate with a higher virulence potential in *A. baumannii*. However, this highlights that low capsulation levels characterizes weakly virulent phenotypes, showing that *A. baumannii* bacteria required capsule deposition for full virulence. This is in agreement with previous studies showing that genetically manipulated capsule deficient *A. baumannii* strains have decreased virulence levels (Talyansky et al., 2021; Whiteway et al., 2021). As the virulence does not directly correlate with a specific KL or OCL type, we can conclude that the KL or OCL are not solely responsible for *A. baumannii* virulence in the tested conditions, which might require multifactorial influence. Taken together, these observations show that the reference strain AB5075 is a good bacterial model to study the virulence potential in *G. mellonella* while the less virulent strains ATCC19606 and ATCC17978 may be used in studies tackling down the modern clinical isolates exhibiting decreased virulence in *G. mellonella*.

Figure 6: *In vivo* virulence of several modern *A. baumannii* isolates determined in *G. mellonella* model. X axis,

days after inoculation and Y axis, percentage of living *G. mellonella*. The control condition is the PS without bacteria.

Discussion

The 43 modern MDR clinical isolates and four reference strains of *A. baumannii* were whole-genome sequenced, *de novo* assembled and analyzed in the context of genotype and phenotype. We identified 12 different ST groups in our collection of 43 modern clinical isolates. While the reference strain AB5075-VUB belonged to less frequently occurring ST1 the reference strains ATCC19606-VUB (ST52), ATCC17978-VUB (ST437) and DSM30011-VUB (ST738) did not reflect the current trends of ST in clinical settings but rather rare sequence types. The lack of representation of the ST of the clinical isolates is expectable only in the case of DSM30011-VUB as this strain has environmental origin (plant microbiota). The ST2 group, previously described as one important and clinically relevant group is also the most widely disseminated ST among the complete and draft genomes available (Hamidian and Nigro, 2019). Most of the modern clinical isolates of our collection belonged to ST2, yet none of the reference strains represented this sequence type.

Our phylogenetic analysis (Figure 1) identified several clades, mostly in accordance with the ST of the isolates. However, the reference strains DSM30011-VUB, ATCC17978-VUB and ATCC19606-VUB formed a cluster with the least abundant sequence types of the clinical isolates of *A. baumannii* [except AB226-VUB (ST604)]. Only this cluster consisted of the isolates which all lacked *adeC* and *bauA* genes which are discussed below, suggesting an extreme genetic diversity which represents only a minor proportion of the current clinical isolates of *A. baumannii*. On the other hand, from the four reference strains, only AB5075-VUB was the most similar to the modern clinical strains of *A. baumannii* in regard to OCL and virulence genes. When considering AB5075-VUB capsule production, its phenotype was

resembling phenotypes of the clinical isolates with low production. Nevertheless, similarly to the other reference strains, it lacked *bauA* and *adeC*. The lack of the combination of these two virulence genes was also detected in ten modern clinical isolates proving that AB5075-VUB still shares partial similarity with circulating clinical strains of *A. baumannii*. The described and listed virulence genes in our study only account for a small amount of the virulence genes as only known can be detected and possibly novel virulence genes remain to be identified. Noteworthy, regardless of observed discrepancy in detection of *adeFGH* operon using VFDB 2022 and MEGARes 2.0 databases, the absence of *adeFGH* was described previously (Ardehali et al., 2019; Coyne et al., 2010).

Capsule heterogeneity is a landmark of *A. baumannii* bacteria. The surface polysaccharides play key roles in fitness and virulence of *A. baumannii* and protects it from the environment, increases resistance to antimicrobial compounds and helps to evade the host immune system (Geisinger and Isberg, 2015; Weber et al., 2016). There are more than 128 KL types identified so far, and this variability demonstrates the diversity which must be surveilled in the modern clinical isolates as the capsular polysaccharide is a potential target for therapeutical agents and vaccines (Yang et al., 2017). In our collection of 43 modern clinical isolates of MDR *A. baumannii*, KL40 (10/43) dominated while KL3 was detected in five isolates.

In our study, the most prevalent locus encoding outer-core lipooligosaccharide (OCL) type in the modern clinical isolates of MDR *A. baumannii* was OCL1 (31/43). However, none of the reference strains represented this most prevalent OCL1 type as they belonged to OCL2 (AB5075-VUB and ATCC17978-VUB), OCL3 (ATCC19606-VUB) and OCL6 (DSM30011-VUB) suggesting their rarefaction in following the current epidemiological trends.

Two reference strains (DSM30011-VUB and AB5075-VUB) in this study lacked *bap* gene encoding biofilm associated protein which could influence the studies exploring biofilm properties using these reference strains. However, the gene *bap* was found in ATCC17978-

VUB and ATCC19606-VUB with 86% identity (VFDB 2022) same as in three clinical isolates (AB40-VUB, AB32-VUB and AB21-VUB), therefore assigned as undetected in the Figure 1 as the identity falls under the applied threshold of 90%. The *bap* encodes protein required for formation of three-dimensional biofilm towers and water channels on abiotic and biotic surfaces such as polypropylene, polystyrene, and titanium (Brossard and Campagnari, 2012). Bap protein is also involved in adherence of *A. baumannii* to human bronchial epithelial cells and human neonatal keratinocytes (Brossard and Campagnari, 2012). Moreover, nearly half of the examined strains (20/47) including four reference strain did not carry *bauA* encoding iron-regulated outer membrane protein BauA. BauA protein provides protection against sepsis caused by *A. baumannii* and was also identified as a vaccine candidate (Aghajani et al., 2019; Ni et al., 2017). Interestingly, six strains (including two reference strains DSM30011-VUB, ATCC19606-VUB and four clinical isolates AB177-VUB, AB186-VUB, AB40-VUB and AB21-VUB) encoded membrane fusion protein MexE protein, part of RND efflux pump from *Pseudomonas aeruginosa* (Köhler et al., 1999). Notably, the very same six strains were lacking a gene encoding membrane fusion protein AdeF from AdeFGH RND efflux pump, possibly restoring its function as AdeF and MexE share 50% homology. However, using the VFDB 2022 database, all clinical isolates and reference strains encoded *adeFGH* operon.

The deficiency of the clinical isolates and the reference strains in hemolytic and protease activities is in agreement with the fact that only some species of *Acinetobacter* genus, e.g., *Acinetobacter haemolyticus* (Touchon et al., 2014) are capable of such phenotype. Even despite this shared phenotypical trait, there was a high level of diversity of macrocolonies, where the reference strains represented only two variants out of five types observed in the clinical strains. Several modern isolates show a constitutive mucoid phenotype that is not observed in the reference strains. Isolates belonging to the same clusters (Figure 1) do not show the same ultrastructure, showing a high diversity even within the same phylogenetic group. To be noted,

also external events such as gene disruption can affect the phenotype of the macrocolony, as was observed in AB5075-UW by Perez-Varela (Pérez-Varela et al., 2020) by disrupting *relA* ortholog (*ABUW_3302*) using transposon insertion. Taken together, this points out the insufficiency of the reference strains in grasping the complete phenotypical (and genotypical) diversity of the modern clinical isolates.

The natural competence for transformation is one of the ways of horizontal gene transfer *A. baumannii* uses to acquire extracellular DNA from the environment and incorporates it into its own genome via homologous recombination (Dubnau and Blokesch, 2019). We observed that the competence to be naturally transformed varied within clinical isolates of *A. baumannii* from which 13 were transformed, 18 were not and 12 were intrinsically resistant to apramycin, therefore unable to assess. This diverse trend was copied by the reference strains as well as AB5075-VUB and DSM30011-VUB were successfully transformed while ATCC17978-VUB was not and ATCC19696-VUB showed intrinsic resistance to apramycin. There are multiple factors influencing the ability of *A. baumannii* to be naturally transformed such as presence of the H-NS (Le et al., 2021) which was present in each case within our isolates and strains. However, the major role is played by type IV pilus genes (Leong et al., 2017) which are growth phase dependent (Vesel and Blokesch, 2021), and might be the explanation of some isolates and strains not being transformed. However, the tested conditions of natural competence were standardized pointing out further physiological diversity within *A. baumannii* clinical isolates and reference strains. Despite the proven relevance of the clinical isolates of our collection (collected as problematic and modern nosocomial isolates), we cannot rule out a bias to certain extend.

We observe a high diversity in production of the capsular polysaccharide using direct and indirect visualization methods. We show a correlation between capsule abundance and density levels, but correlation does not mean causation. We cannot rule out the possibility that the

capsule type *per se* (and not only the capsule abundance) or other factors, influence the density of *A. baumannii* bacteria. The fact that widely used reference strains show low to medium encapsulation degrees add an additional reason why reference strains should be carefully used and argue in favor of considering the strain AB5075-VUB as the best representative bacterial model out of the four reference strains tested in this study. However, a rather complex solution to selection of proper strain to be used in a specific study is needed such as Acinetobase (Valcek et al., unpublished). Acinetobase is a comprehensive database providing the community with genotype, phenotype and the strain of *A. baumannii* itself.

The *Galleria mellonella* infection model proved itself as a valuable source of information on the virulence level of *A. baumannii*. This model also highlighted AB5075-VUB to be more virulent than ATCC19606-VUB and ATCC17978-VUB in the tested conditions (Jacobs et al., 2014). These results support the usage of modern clinical isolates for study of virulence, hence other highly virulent isolates such as hypervirulent *A. baumannii* LAC-4 (Ou et al., 2015) should be considered as well.

As constitutive mucoid strains were observed only amongst the group of the modern MDR clinical isolates, we wondered if this phenotype could be associated with a higher *in vivo* virulence potential. The virulence in *G. mellonella* model varied for the tested clinical isolates and the reference strains and while a constitutive mucoid phenotype does not correlate with a higher virulence, we confirm using modern clinical isolates that low capsule production impedes full virulence in *A. baumannii*. These observations do not confirm the results of Shan et al., (Shan et al., 2021) who concluded that the mucoid *A. baumannii* isolates were more hypervirulent than the nonmucoid strains. This discrepancy may point towards multifactorial background of hypervirulence.

The signal(s) or conditions regulating capsule production remain to be determined. Noteworthy, the isolates AB193-VUB and AB213-VUB with higher integrity of the CPS layer (Figure 5) have shown higher virulence in *G. mellonella* (Figure 6) than isolates with dispersed CPS. The study of genetic features which are not shared by the majority of *A. baumannii* isolates (soft-core, shell and cloud genes (Cummins et al., 2022)) may lead to novel discoveries as well. However, the global impact of the clinical importance (drug therapies or target-driven drug discoveries) will suffer from linking the specific genes and features only to certain isolate or lineage.

Conclusion

A. baumannii are heterogenous bacteria, both at the genetic and phenotypic levels. In this study, we characterized 43 modern clinical isolates from different phylogenetic groups and 4 reference strains with common but also very different behaviors. Therefore, the reference strains tested in our study do not cover the whole heterogeneity found in the modern isolates of *A. baumannii*. The studies previously published using these reference strains built a strong state of the art in the *A. baumannii* field and beyond, showing their usefulness. However, the data presented in our study show that the specific use of one or only a limited subset of reference strains can hinder important processes characterizing clinically relevant isolates and the *A. baumannii* bacteria as a whole. As an answer to that identified pitfall, we propose a variable collection of modern clinical isolates that are characterized at the genetic and phenotypic levels, covering the full range of the phenotypic spectrum, with five different macrocolony type groups, from avirulent to hyper virulent phenotype, and with non-capsulated to hyper mucoid strains, with intermediate phenotypes as well. This will allow selecting a reference strain rationally, facilitated by the new Acinetobase (Valcek et al., unpublished) platform, which suits the needs of an ongoing study with a particular biological question. This is especially important for new

antimicrobial screening purposes, for which conserved targets amongst a significant proportion of problematic *A. baumannii* isolates is a prerequisite. While strain specific observation remains interesting *per se*, in the context of such a drastic heterogeneity, any new identified target, antimicrobial compound, or fundamental observation deserved to be tested on diverse relevant *A. baumannii* isolates.

Data availability

The short- and long-read sequences were deposited in GenBank under BioProject PRJNA734485 and PRJNA798866, respectively.

Funding

This project was supported by the Flanders Institute for Biotechnology (VIB) and has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 748032. KN was supported by the Erasmus + program KA131-HED.

Acknowledgements

We are grateful to the URBM and URBE research groups, as well as the Electron Microscopy Service from UNamur, for the access to their equipment and their expertise. We thank Ivan Mateus from the Department of Ecology and Evolution, University of Lausanne, Lausanne,

Switzerland for a fruitful discussion of initial bioinformatical analyses. We thank the National Reference Laboratory for Monitoring of Antimicrobial Resistance in Gram-negative Bacteria, CHU Mont-Godinne, Université Catholique de Louvain (UCL), Yvoir (Belgium) for providing the modern clinical isolates.

Competing interests

None to declare.

Contribution

CP, CVDH and ER performed phenotypical experiments. AV, CVDH and KN performed bioinformatical analyses. CW extracted DNA for the long-read sequencing. MB, CP, CVDH and TC performed the infections of *Galleria mellonella*. TDP, WDC and MS set up the LRS strategy, sample, library preparation and sequencing. JK provided her expertise in KL and OCL identification. AV and CVDH wrote the manuscript

References

- Aghajani Z, Rasooli I, Mousavi Gargari SL. 2019. Exploitation of two siderophore receptors, BauA and BfnH, for protection against *Acinetobacter baumannii* infection. *APMIS* **127**:753–763. doi:10.1111/apm.12992
- Arbatsky NP, Shneider MM, Kenyon JJ, Shashkov AS, Popova A v., Miroshnikov KA, Volozhantsev N v., Knirel YA. 2015. Structure of the neutral capsular polysaccharide of *Acinetobacter baumannii* NIPH146 that carries the KL37 capsule gene cluster. *Carbohydrate Research* **413**:12–15. doi:10.1016/J.CARRES.2015.05.003
- Ardehali SH, Azimi T, Fallah F, Owrang M, Aghamohammadi N, Azimi L. 2019. Role of efflux pumps in reduced susceptibility to tigecycline in *Acinetobacter baumannii*. *New Microbes and New Infections* **30**:100547. doi:10.1016/J.NMNI.2019.100547
- Ardisson S, Fumeaux C, Bergé M, Beaussart A, Théraulaz L, Radhakrishnan SK, Dufrêne YF, Viollier PH. 2014. Cell cycle constraints on capsulation and bacteriophage susceptibility. *eLife* **3**:1–30. doi:10.7554/ELIFE.03587

- 625 Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: A flexible trimmer for Illumina sequence
626 data. *Bioinformatics* **30**:2114–2120. doi:10.1093/bioinformatics/btu170
- 627 Boll JM, Tucker AT, Klein DR, Beltran AM, Brodbelt JS, Davies BW, Trent MS. 2015.
628 Reinforcing lipid a acylation on the cell surface of *Acinetobacter baumannii* promotes
629 cationic antimicrobial peptide resistance and desiccation survival. *mBio* **6**:1–11.
630 doi:10.1128/MBIO.00478-15/SUPPL_FILE/MBO003152328ST2.PDF
- 631 Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
632 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender
633 JK, Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M,
634 Anjum MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wieczorek K, Amaro A,
635 Clemente L, Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder
636 4.0 for predictions of phenotypes from genotypes. *Journal of Antimicrobial Chemotherapy*
637 **75**:3491–3500. doi:10.1093/JAC/DKAA345
- 638 Bouvet PJM, Grimont PAD. 1986. Taxonomy of the Genus *Acinetobacter* with the Recognition
639 of *Acinetobacter baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter*
640 *johnsonii* sp. nov., and *Acinetobacter junii* sp. nov. and Emended Descriptions of
641 *Acinetobacter calcoaceticus* and *Acinetobacter lwoffii*. *International Journal of*
642 *Systematic and Evolutionary Microbiology* **36**:228–240. doi:10.1099/00207713-36-2-228
- 643 Bravo Z, Orruño M, Parada C, Kaberdin VR, Barcina I, Arana I. 2016. The long-term survival
644 of *Acinetobacter baumannii* ATCC 19606T under nutrient-deprived conditions does not
645 require the entry into the viable but non-culturable state. *Archives of Microbiology*
646 **198**:399–407. doi:10.1007/s00203-016-1200-1
- 647 Brossard KA, Campagnari AA. 2012. The *Acinetobacter baumannii* Biofilm-Associated
648 Protein Plays a Role in Adherence to Human Epithelial Cells. doi:10.1128/IAI.05913-11
- 649 Centers for Disease Control U. 2019. Antibiotic Resistance Threats in the United States, 2019.
650 doi:10.15620/cdc:82532
- 651 Chiang SR, Jung F, Tang HJ, Chen CH, Chen CC, Chou HY, Chuang YC. 2018. Desiccation
652 and ethanol resistances of multidrug resistant *Acinetobacter baumannii* embedded in
653 biofilm: The favorable antiseptic efficacy of combination chlorhexidine gluconate and
654 ethanol. *Journal of Microbiology, Immunology and Infection* **51**:770–777.
655 doi:10.1016/j.jmii.2017.02.003
- 656 Chin CY, Tipton KA, Farokhyfar M, Burd EM, Weiss DS, Rather PN. 2018. A high-frequency
657 phenotypic switch links bacterial virulence and environmental survival in *Acinetobacter*
658 *baumannii*. *Nature Microbiology* 2018 3:5 **3**:563–569. doi:10.1038/s41564-018-0151-5
- 659 Coyne S, Rosenfeld N, Lambert T, Courvalin P, Périchon B. 2010. Overexpression of
660 resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in
661 *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* **54**:4389–4393.
662 doi:10.1128/AAC.00155-10/ASSET/051BDFEF-DB1A-4F55-B6EB-
663 323DD38348B4/ASSETS/GRAPHIC/ZAC9991093410002.JPEG
- 664 Cummins EA, Hall RJ, McInerney JO, McNally A. 2022. Prokaryote pangenomes are dynamic
665 entities. *Current Opinion in Microbiology* **66**:73–78. doi:10.1016/J.MIB.2022.01.005
- 666 da Silva G, Domingues S. 2016. Insights on the Horizontal Gene Transfer of Carbapenemase
667 Determinants in the Opportunistic Pathogen *Acinetobacter baumannii*. *Microorganisms*
668 **4**:29. doi:10.3390/microorganisms4030029
- 669 de Coster W, D’hert S, Schultz DT, Cruts M, van Broeckhoven C. 2018. NanoPack: visualizing
670 and processing long-read sequencing data. doi:10.1093/bioinformatics/bty149
- 671 de Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL,
672 Walker MJ. 2020. Antimicrobial Resistance in ESKAPE Pathogens. doi:10.1128/CMR

- de Silva PM, Chong P, Fernando DM, Westmacott G, Kumar A. 2017. Effect of Incubation Temperature on Antibiotic Resistance and Virulence Factors of *Acinetobacter baumannii* ATCC 17978. doi:10.1128/AAC.01514-17
- Dong C, Beis K, Nesper J, Brunkan AL, Clarke BR, Whitfield C, Naismith JH. 2006. The structure of Wza, the translocon for group 1 capsular polysaccharides in *Escherichia coli*, identifies a new class of outer membrane protein. *Nature* **444**:226. doi:10.1038/NATURE05267
- Doster E, Lakin SM, Dean CJ, Wolfe C, Young JG, Boucher C, Belk KE, Noyes NR, Morley PS. 2020. MEGARes 2.0: A database for classification of antimicrobial drug, biocide and metal resistance determinants in metagenomic sequence data. *Nucleic Acids Research* **48**:D561–D569. doi:10.1093/nar/gkz1010
- Dubnau D, Blokesch M. 2019. Mechanisms of DNA Uptake by Naturally Competent Bacteria. <https://doi.org/10.1146/annurev-genet-112618-043641> **53**:217–237. doi:10.1146/ANNUREV-GENET-112618-043641
- Gaiarsa S, Batisti Biffignandi G, Esposito EP, Castelli M, Jolley KA, Brisse S, Sasser D, Zarrilli R. 2019. Comparative analysis of the two *Acinetobacter baumannii* multilocus sequence typing (MLST) schemes. *Frontiers in Microbiology* **10**. doi:10.3389/fmicb.2019.00930
- Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski D v., Brittnacher MJ, Manoil C. 2015. Resources for genetic and genomic analysis of emerging pathogen *Acinetobacter baumannii*. *Journal of Bacteriology* **197**:2027–2035. doi:10.1128/JB.00131-15
- Geisinger E, Huo W, Hernandez-Bird J, Isberg RR. 2019. *Acinetobacter baumannii*: Envelope Determinants That Control Drug Resistance, Virulence, and Surface Variability. <https://doi.org/10.1146/annurev-micro-020518-115714> **73**:481–506. doi:10.1146/ANNUREV-MICRO-020518-115714
- Geisinger E, Isberg RR. 2015. Antibiotic Modulation of Capsular Exopolysaccharide and Virulence in *Acinetobacter baumannii*. *PLOS Pathogens* **11**:e1004691. doi:10.1371/journal.ppat.1004691
- Hamidian M, Nigro SJ. 2019. Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microbial Genomics*. doi:10.1099/mgen.0.000306
- Harding CM, Hennon SW, Feldman MF. 2017. Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nature Reviews Microbiology* **2017** **16**:2 **16**:91–102. doi:10.1038/nrmicro.2017.148
- Hernando-Amado S, Coque TM, Baquero F, Martínez JL. 2019. Defining and combating antibiotic resistance from One Health and Global Health perspectives. *Nature Microbiology*. doi:10.1038/s41564-019-0503-9
- Holley G, Beyter D, Ingimundardottir H, Møller PL, Kristmundsdottir S, Eggertsson HP, Halldorsson B v. 2021. Ratatosk: hybrid error correction of long reads enables accurate variant calling and assembly. *Genome Biology* **22**:1–22. doi:10.1186/S13059-020-02244-4/FIGURES/8
- Imperi F, Antunes LCS, Blom J, Villa L, Iacono M, Visca P, Carattoli A. 2011. The genomics of *Acinetobacter baumannii*: Insights into genome plasticity, antimicrobial resistance and pathogenicity. *IUBMB Life* **63**:1068–1074. doi:10.1002/iub.531
- Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, Owen MT, Hallock JD, Kwak YI, Summers A, Li CZ, Rasko DA, Penwell WF, Honnold CL, Wise MC, Waterman PE, Lesho EP, Stewart RL, Actis LA, Palys TJ, Craft DW, Zurawski D v. 2014. AB5075, a highly virulent isolate of

- Acinetobacter baumannii*, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. *mBio* **5**. doi:10.1128/mBio.01076-14
- Kenyon JJ, Hall RM. 2013. Variation in the Complex Carbohydrate Biosynthesis Loci of *Acinetobacter baumannii* Genomes. *PLoS ONE* **8**:e62160. doi:10.1371/journal.pone.0062160
- Kenyon JJ, Nigro SJ, Hall RM. 2014. Variation in the OC Locus of *Acinetobacter baumannii* Genomes Predicts Extensive Structural Diversity in the Lipooligosaccharide. *PLoS ONE* **9**:e107833. doi:10.1371/journal.pone.0107833
- Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. *Journal of Bacteriology* **181**:6300–6305. doi:10.1128/jb.181.20.6300-6305.1999
- Kolmogorov M, Yuan J, Lin Y, Pevzner PA. 2019. Assembly of long, error-prone reads using repeat graphs. *Nature Biotechnology* **37**:540–546. doi:10.1038/s41587-019-0072-8
- Kon H, Schwartz D, Temkin E, Carmeli Y, Lellouche J. 2020. Rapid identification of capsulated *Acinetobacter baumannii* using a density-dependent gradient test. *BMC Microbiology* **20**:1–11. doi:10.1186/s12866-020-01971-9
- Le C, Pimentel C, Tuttobene MR, Subils T, Escalante J, Nishimura B, Arriaga S, Rodgers D, Bonomo RA, Sieira R, Tolmasky ME, Ramírez MS. 2021. Involvement of the Histone-Like Nucleoid Structuring Protein (H-NS) in *Acinetobacter baumannii*'s Natural Transformation. *Pathogens* **2021**, Vol 10, Page 1083 **10**:1083. doi:10.3390/PATHOGENS10091083
- Leong CG, Bloomfield RA, Boyd CA, Dornbusch AJ, Lieber L, Liu F, Owen A, Slay E, Lang KM, Lostroh CP. 2017. The role of core and accessory type IV pilus genes in natural transformation and twitching motility in the bacterium *Acinetobacter baylyi*. *PLOS ONE* **12**:e0182139. doi:10.1371/JOURNAL.PONE.0182139
- Letunic I, Bork P. 2019. Interactive Tree of Life (iTOL) v4: Recent updates and new developments. *Nucleic Acids Research* **47**:W256–W259. doi:10.1093/nar/gkz239
- Liu B, Zheng D, Zhou S, Chen L, Yang J. 2022. VFDB 2022: a general classification scheme for bacterial virulence factors. *Nucleic Acids Research* **50**:D912–D917. doi:10.1093/NAR/GKAB1107
- Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, Kashef Hamadani BH, Kumaran EAP, McManigal B, Agarwal R, Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J, Carvalheiro C, Castañeda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchiù S, Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe S, Day NPJ, de Luca M, Dokova K, Dramowski A, Dunachie SJ, Eckmanns T, Eibach D, Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garrett D, Gastmeier P, Giref AZ, Greer RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins S, Iregbu KC, Jacobs J, Jarovsky D, Javanmardi F, Khorana M, Kissoon N, Kobeissi E, Kostyanev T, Krapp F, Krumkamp R, Kumar A, Kyu HH, Lim C, Limmathurotsakul D, Loftus MJ, Lunn M, Ma J, Mturi N, Munera-Huertas T, Musicha P, Mussi-Pinhata MM, Nakamura T, Nanavati R, Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Olivas-Martinez A, Oliaro P, Ooko E, Ortiz-Brizuela E, Peleg AY, Perrone C, Plakkal N, Ponce-de-Leon A, Raad M, Ramdin T, Riddell A, Roberts T, Robotham JV, Roca A, Rudd KE, Russell N, Schnall J, Scott JAG, Shivamallappa M, Sifuentes-Osornio J, Steenkeste N, Stewardson AJ, Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Turner C, Turner P, van Doorn HR, Velaphi S, Vongpradith A, Vu H, Walsh T, Waner S, Wangrangsimakul T, Wozniak T, Zheng P, Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M. 2022. Global

- burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* **399**:629–655. doi:10.1016/S0140-6736(21)02724-0
- Ni Z, Chen Y, Ong E, He Y. 2017. Antibiotic resistance determinant-focused *Acinetobacter baumannii* vaccine designed using reverse vaccinology. *International Journal of Molecular Sciences* **18**. doi:10.3390/ijms18020458
- Niu T, Guo L, Luo Q, Zhou K, Yu W, Chen Y, Huang C, Xiao Y. 2019. Wza gene knockout decreases *Acinetobacter baumannii* virulence and affects Wzy-dependent capsular polysaccharide synthesis. <https://doi.org/10.1080/21505594.2019.1700659> **11**:1–13. doi:10.1080/21505594.2019.1700659
- Ou HY, Kuang SN, He X, Molgora BM, Ewing PJ, Deng Z, Osby M, Chen W, Xu HH. 2015. Complete genome sequence of hypervirulent and outbreak-associated *Acinetobacter baumannii* strain LAC-4: epidemiology, resistance genetic determinants and potential virulence factors. *Scientific Reports* **5**:1 5:1–13. doi:10.1038/srep08643
- Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: Rapid large-scale prokaryote pan genome analysis. *Bioinformatics* **31**:3691–3693. doi:10.1093/bioinformatics/btv421
- Pérez-Varela M, Tierney ARP, Kim J-S, Vázquez-Torres A, Rather P. 2020. Characterization of RelA in *Acinetobacter baumannii*. doi:10.1128/JB.00045-20
- Poirel L, Nordmann P. 2006. Carbapenem resistance in *Acinetobacter baumannii*: Mechanisms and epidemiology. *Clinical Microbiology and Infection*. doi:10.1111/j.1469-0691.2006.01456.x
- Repizo GD, Viale AM, Borges V, Cameranesi MM, Taib N, Espariz M, Brochier-Armanet C, Gomes JP, Salcedo SP. 2017. The Environmental *Acinetobacter baumannii* Isolate DSM30011 Reveals Clues into the Preantibiotic Era Genome Diversity, Virulence Potential, and Niche Range of a Predominant Nosocomial Pathogen. *Genome Biology and Evolution* **9**:2292–2307. doi:10.1093/GBE/EVX162
- Roussin M, Rabarioelina S, Cluzeau L, Cayron J, Lesterlin C, Salcedo SP, Bigot S. 2019. Identification of a Contact-Dependent Growth Inhibition (CDI) System That Reduces Biofilm Formation and Host Cell Adhesion of *Acinetobacter baumannii* DSM30011 Strain. *Frontiers in Microbiology* **10**:2450. doi:10.3389/fmicb.2019.02450
- Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. 2021. *Acinetobacter baumannii*: An Ancient Commensal with Weapons of a Pathogen. *Pathogens* **2021, Vol 10, Page 387** **10**:387. doi:10.3390/PATHOGENS10040387
- Seemann T. 2014. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics* **30**:2068–2069. doi:10.1093/bioinformatics/btu153
- Senchenkova SN, Shashkov AS, Popova A v., Shneider MM, Arbatsky NP, Miroshnikov KA, Volozhantsev N v., Knirel YA. 2015. Structure elucidation of the capsular polysaccharide of *Acinetobacter baumannii* AB5075 having the KL25 capsule biosynthesis locus. *Carbohydrate Research* **408**:8–11. doi:10.1016/J.CARRES.2015.02.011
- Shan W, Zhang H, Kan J, Yin M, Zhang J, Wan L, Chang R, Li M. 2021. Acquired mucoid phenotype of *Acinetobacter baumannii*: Impact for the molecular characteristics and virulence. *Microbiological Research* **246**:126702. doi:10.1016/J.MICRES.2021.126702
- Stamatakis A. 2006. RAxML-VI-HPC: Maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics* **22**:2688–2690. doi:10.1093/bioinformatics/btl446
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outtersen K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson L, Hansen P, Singh N, Theuretzbacher U, Magrini N. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of

- antibiotic-resistant bacteria and tuberculosis. *www.thelancet.com/infection* **18**.
doi:10.1016/S1473-3099(17)30753-3
- Talyansky Y, Nielsen TB, Yan J, Carlino-Macdonald U, di Venanzio G, Chakravorty S, Ulhaq A, Feldman MF, Russo TA, Vinogradov E, Luna B, Wright MS, Adams MD, Spellberg B. 2021. Capsule carbohydrate structure determines virulence in *Acinetobacter baumannii*. *PLOS Pathogens* **17**:e1009291. doi:10.1371/JOURNAL.PPAT.1009291
- Tipton KA, Dimitrova D, Rather PN. 2015. Phase-variable control of multiple phenotypes in *Acinetobacter baumannii* strain AB5075. *Journal of Bacteriology* **197**:2593–2599. doi:10.1128/JB.00188-15
- Touchon M, Cury J, Yoon EJ, Krizova L, Cerqueira GC, Murphy C, Feldgarden M, Wortman J, Clermont D, Lambert T, Grillot-Courvalin C, Nemec A, Courvalin P, Rocha EPC. 2014. The genomic diversification of the whole *Acinetobacter* genus: Origins, mechanisms, and consequences. *Genome Biology and Evolution* **6**:2866–2882. doi:10.1093/gbe/evu225
- Valcek A, Bogaerts P, Denis O, Huang T-D, Henst C van der. 2021. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* strains in Belgian acute-care hospitals. *medRxiv* 2021.07.06.21259728. doi:10.1101/2021.07.06.21259728
- van der Henst C, Vanhove AS, Drebes Dörr NC, Stutzmann S, Stoudmann C, Clerc S, Scignari T, Maclachlan C, Knott G, Blokesch M. 2018. Molecular insights into *Vibrio cholerae*'s intra-amoebal host-pathogen interactions. *Nature Communications* **2018** 9:1 **9**:1–13. doi:10.1038/s41467-018-05976-x
- Vesel N, Blokesch M. 2021. Pilus Production in *Acinetobacter baumannii* Is Growth Phase Dependent and Essential for Natural Transformation. doi:10.1128/JB.00034-21
- Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: An Integrated Tool for Comprehensive Microbial Variant Detection and Genome Assembly Improvement. *PLoS ONE* **9**:e112963. doi:10.1371/journal.pone.0112963
- Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Balthasar JP, Russo TA. 2017. The Capsular Polysaccharide of *Acinetobacter baumannii* Is an Obstacle for Therapeutic Passive Immunization Strategies. *Infection and Immunity* **85**. doi:10.1128/IAI.00591-17
- Weber BS, Harding CM, Feldman MF. 2016. Pathogenic *Acinetobacter*: from the Cell Surface to Infinity and Beyond. doi:10.1128/JB.00906-15
- Whiteway C, Breine A, Philippe C, van der Henst C. 2022. *Acinetobacter baumannii*. *Trends in Microbiology* **30**:199–200. doi:10.1016/J.TIM.2021.11.008
- Whiteway C, Valcek A, Philippe C, Strazisar M, de Pooter T, Mateus I, Breine A, Van der Henst C. 2021. Scarless excision of an insertion sequence restores capsule production and virulence in *Acinetobacter baumannii*. *The ISME Journal* **2022** 1–5. doi:10.1038/s41396-021-01179-3
- Wick RR, Heinz E, Holt KE, Wyres KL, Diekema DJ. 2018. Kaptive Web: User-Friendly Capsule and Lipopolysaccharide Serotype Prediction for *Klebsiella* Genomes. *jcm.asm.org | Journal of Clinical Microbiology* **56**:197–215. doi:10.1128/JCM.00197-18
- Wyres KL, Cahill SM, Holt KE, Hall RM, Kenyon JJ. 2020. Identification of *Acinetobacter baumannii* loci for capsular polysaccharide (KL) and lipooligosaccharide outer core (OCL) synthesis in genome assemblies using curated reference databases compatible with kaptive. *Microbial Genomics* **6**:e000339. doi:10.1099/mgen.0.000339
- Yang FL, Lou TC, Kuo SC, Wu WL, Chern J, Lee YT, Chen ST, Zou W, Lin NT, Wu SH. 2017. A medically relevant capsular polysaccharide in *Acinetobacter baumannii* is a potential vaccine candidate. *Vaccine* **35**:1440–1447. doi:10.1016/j.vaccine.2017.01.060

868

869

870 **Figure 1:** A depiction of (A) Conserved and total gene numbers in the pangenome. (B) Novel and unique gene numbers in the pangenome. These graphs indicate how the
871 pangenome varies as genomes are added. (C) Pangenome pie chart showing the number of core and accessory genes. Accessory genes were divided into soft core, shell and
872 cloud genes.

873